HOME >> BIOLOGY >> NEWS
JCI table of contents, July 15, 2003

Cell Biology in Sydney, Australia, have identified a novel function for BAFF: it acts as a specific survival factor for Ig-secreting cells derived from memory B cells. The study suggest that in human autoimmune diseases, elevated levels of serum BAFF may contribute to the disease process by not only breaking tolerance at the immature/transitional B cell stage of development, but by also enhancing plasmablast survival.

TITLE: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells

AUTHOR CONTACT:
Stuart Tangye
Centenary Institute of Cancer Medicine and Cell Biology, Newtown, Australia.
Phone: 61-2-9565-6127
Fax: 61-2-9565-6103
E-mail: s.tangye@centenary.usyd.edu.au

View the PDF of this article at: https://www.the-jci.org/press/18025.pdf


Secret to controlling thyroid hormone production

Originating in the thyroid, the prohormone thyroxine is converted to triiodothyronine, which is essential in brain development, growth, and metabolism. A study from researchers at Brigham and Women's Hospital in Boston, reveals a novel mechanism for controlling triiodothyronine production that demonstrates the first example of enzyme activity being restored by deubiquitination.

TITLE: Deubiquitination of type 2 iodothyronine deiodinase by von HippelLindau proteininteracting deubiquitinating enzymes regulates thyroid hormone activation

AUTHOR CONTACT:
Antonio C. Bianco
Harvard University, Boston, Massachusetts, USA.
Phone: 617-525-5153
Fax: 617-731-4718
E-mail: abianco@partners.org

View the PDF of this article at: https://www.the-jci.org/press/18348.pdf

ACCOMPANYING COMMENTARY:
Ubiquitinated dei
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Jul-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 16 August, 2004
7. JCI table of contents, 2 August, 2004
8. When male fish hum, females swim in, thanks to hormones, adaptable hearing
9. JCI table of contents, 1 July 2004
10. Search and destroy protein turns tables on HIV
11. JCI table of contents, 15 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents July

(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... 24, 2015 The global ... USD 27.8 billion by 2022, growing at an estimated ... a new study by Grand View Research, Inc. Development ... to result in significant reduction in cost of sequencing ... and usage rates of next generation sequencing throughout the ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5
Cached News: